ArticleNature2022
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
Abstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 347 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
347citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
347 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters.EBioMedicine · 2023Pooled it
- Pooled it
- Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review.Human vaccines & immunotherapeutics · 2022Pooled it
- Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.Antimicrobial agents and chemotherapy · 2025Trial
- Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial.Nature communications · 2024Trial
- Trial
- Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents.Nature communications · 2022Trial
- Broad cross-T cell immunity between emerging SARS-CoV-2 serotypes waved by spike-signature mutations.Emerging microbes & infections · 2026Article
- An Engineered Spike Immunogen Drives Broad Protection of a Bivalent Recombinant Protein COVID-19 Vaccine in Animal Models.Viruses · 2026Article
- Article
- Development of a recombinant single-cycle influenza viral vector as an intranasal vaccine against SARS-CoV-2.Scientific reports · 2026Article
- Article
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
- Surrogate virus neutralization test as a scalable and reliable tool for immune surveillance in booster-vaccinated populations.Scientific reports · 2026Article
- A modular three in one mucosal vaccine against three antigenic clusters of ACE2 using sarbecoviruses.NPJ vaccines · 2026Article
- Antibody escape drives emergence of diverse spike haplotypes resembling variants of concern in persistent SARS-CoV-2 infections.Cell reports. Medicine · 2026Article
- SARS-CoV-2 variants: biology, pathogenicity, immunity and control.Nature reviews. Microbiology · 2026Review
- Development of a Recombinant Single-Cycle Influenza Viral Vector as an Intranasal Vaccine against SARS-CoV-2 and SARS-like Betacoronaviruses.bioRxiv : the preprint server for biology · 2025Article
- Distinct features of humoral and cellular immunity against Omicron breakthrough infection among chronic liver disease patients: An experience from a follow-up cohort.Human vaccines & immunotherapeutics · 2025Article
287 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Juan Manuel CarreñoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Hala AlshammaryDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Johnstone TcheouDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Gagandeep SinghDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Ariel J RaskinDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Hisaaki KawabataDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Levy A SominskyDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Jordan J ClarkDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Daniel C AdelsbergDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.ORCID http://orcid.org/0000-0003-0591-7136
Dominika A BielakDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Ana Silvia Gonzalez-ReicheDepartment of Genetics and Genomic Sciences, ISMMS, New York, NY, USA.ORCID http://orcid.org/0000-0003-3583-4497
Nicholas DambrauskasCenter for Global Infectious Disease Research, Seattle Children's Research Institute, University of Washington, Seattle, WA, USA.
Vladimir VigdorovichCenter for Global Infectious Disease Research, Seattle Children's Research Institute, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-4195-4858
PSP-PARIS Study Group
Komal SrivastavaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
D Noah SatherCenter for Global Infectious Disease Research, Seattle Children's Research Institute, University of Washington, Seattle, WA, USA.
Emilia Mia SordilloDepartment of Pathology, Molecular and Cell-Based Medicine, ISMMS, New York, NY, USA. emilia.sordillo@mountsinai.org.ORCID http://orcid.org/0000-0001-7787-3051
Goran BajicDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA. goran.bajic@mssm.edu.ORCID http://orcid.org/0000-0003-0480-4324
Harm van BakelDepartment of Genetics and Genomic Sciences, ISMMS, New York, NY, USA. harm.vanbakel@mssm.edu.ORCID http://orcid.org/0000-0002-1376-6916
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA. viviana.simon@mssm.edu.ORCID http://orcid.org/0000-0002-6416-5096
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA. florian.krammer@mssm.edu.ORCID http://orcid.org/0000-0003-4121-776X
Funding
Big Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MNIH HHS S10 OD026880
Abstract
The Omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as well as in a sample from a traveller from South Africa in Hong Kong
Indexed as
Convalescence2019-nCoV Vaccine mRNA-1273AdultAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesFemaleHumansImmune EvasionImmune SeraImmunization, SecondaryModels, MolecularNeutralization Tests2019-nCoV Vaccine mRNA-1273Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmune SeraSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
PMID
35016197What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.